Based on results from ADAURA, in clinical practice, how likely are you to recommend adjuvant chemotherapy prior to adjuvant osimertinib for stage IIA T2bN0 EGFR mutant NSCLC?

Topics: Thoracic Malignancies • Medical Oncology • MD Anderson • NCI-CCC Tumor Board Question • Non-small cell lung cancer • EGFR+ • NCI-CCC Thoracic Tumor Board Question

Answer from: Medical Oncologist at Community Practice

I am unlikely to recommend adjuvant chemotherapy prior to Osimertinib. The 24-month disease-free survival for patients on Osimertinib was identical (89%) regardless of adjuvant chemotherapy administration. Unless long term data shows a significant benefit, I would not recommend adjuvant chemotherapy...

Comments

Medical Oncologist at Johns Hopkins University School of Medicine
There is no long term overall survival benefit ass...

Medical Oncologist at Saint Louise Regional Hospital
One might argue that although the benefit is modes...

Related Questions